Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Ezra E.W. Cohen, Lisle Nabell, Deborah J.L. Wong, Terry A Day, Gregory A. Daniels, Mohammed M. Milhem, Sanjeev Deva, Michael B. Jameson, Orlando Guntinas-Lichius, Mohammed Almubarak, Robert Matthew Strother, Eric D. Whitman, Michael Jon Chisamore, Cynthia Chinedu Obiozor, Teresa Bagulho, Albert Candia, Erick Gamelin, Robert Janssen, Alain Patrick Algazi
Institutions: University of California San Diego, University of Alabama at Birmingham, University of California, Los Angeles, Medical University of South Carolina, University of Iowa, Auckland City Hospital, Waikato Hospital, Jena University Hospital, West Virginia University, Christchurch Hospital, Canterbury District Health Board, Atlantic Health System, Merck & Co., Inc., Rahway, NJ, USA (United States), Dynavax Technologies (United States), University of California, San Francisco
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2947709024